基于GLP-1的疗法在MASH中的应用:从代谢获益到肝纤维化改善。
完整摘要 · 中文译文
纤维化分期是代谢功能障碍相关脂肪性肝病(MASLD)中肝脏相关结局的最强预测因素,支持对伴有F2-F3纤维化的代谢功能障碍相关脂肪性肝炎(MASH)进行药物治疗。胰高血糖素样肽-1(GLP-1)受体激动剂通过减重以及有利的代谢和抗炎效应改善MASLD;临床前研究提示由肝窦内皮细胞介导的不依赖减重的信号传导。早期试验显示脂肪性肝炎消退,但纤维化改善不一致。在III期ESSENCE试验中,每周一次司美格鲁肽2.4 mg在第72周显著提高了达到“脂肪性肝炎消退且肝纤维化无恶化”和“肝纤维化减轻且脂肪性肝炎无恶化”的患者比例,从而在美国获得加速批准,并在日本获批用于伴中度或晚期纤维化的非肝硬化MASH。当活检不适宜时,无创评估可能有助于患者选择和监测,但应答阈值尚需验证。本综述总结了相关证据、机制、患者选择、安全性、监测及挑战。
完整摘要 · 英文原文
The fibrosis stage is the strongest predictor of liver-related outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD), supporting pharmacotherapy for metabolic dysfunction-associated steatohepatitis (MASH) with F2-F3 fibrosis. Glucagon-like peptide-1 (GLP-1) receptor agonists improve MASLD through weight loss and favorable metabolic and anti-inflammatory effects; preclinical studies suggest weight loss-independent signaling mediated by liver sinusoidal endothelial cells. Early trials showed steatohepatitis resolution, but an inconsistent fibrosis improvement. In phase III ESSENCE, weekly semaglutide 2.4 mg significantly increased the proportions of patients achieving "resolution of steatohepatitis with no worsening of liver fibrosis" and a "reduction in liver fibrosis with no worsening of steatohepatitis" at week 72, leading to accelerated approval in the United States and approval in Japan for noncirrhotic MASH with moderate or advanced fibrosis. Non-invasive assessment may support patient selection and monitoring when a biopsy is inappropriate, although response thresholds require validation. This review summarizes the evidence, mechanisms, patient selection, safety, monitoring, and challenges.